

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6606995

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WILDLIFE LABORATORIES, LLC	08/07/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MARANON CAPITAL, L.P., AS AGENT
<b>Street Address:</b>	303 W. MADISON STREET, SUITE 2500
<b>City:</b>	CHICAGO
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60606
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	7795263
<b>Patent Number:</b>	9339498
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)902-1061
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312.577.8034
<b>Email:</b>	oscar.ruiz@katten.com
<b>Correspondent Name:</b>	OSCAR RUIZ C/O KATTEN MUCHIN ROSENMAN
<b>Address Line 1:</b>	525 WEST MONROE STREET
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60661
<b>ATTORNEY DOCKET NUMBER:</b>	339494-00068
<b>NAME OF SUBMITTER:</b>	OSCAR RUIZ
<b>SIGNATURE:</b>	/Oscar Ruiz/
<b>DATE SIGNED:</b>	03/17/2021
<b>Total Attachments: 4</b>	
source=wedgewood second amendment patent security agreement#page1.tif	
source=wedgewood second amendment patent security agreement#page2.tif	
source=wedgewood second amendment patent security agreement#page3.tif	
source=wedgewood second amendment patent security agreement#page4.tif	

## PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT (the "Agreement") made as of this 7<sup>th</sup> day of August, 2020, by Wildlife Laboratories, LLC, a Delaware limited liability company ("Grantor"), in favor of Maranon Capital, L.P., in its capacity as Agent for the Lenders party to the Credit Agreement (defined below) (herein, "Grantee"):

### WITNESSETH

WHEREAS, Grantor, one or more of its affiliates, Grantee and the lenders identified therein are parties to a certain Credit Agreement dated as of July 17, 2018 (as the same may be amended or otherwise modified from time to time, the "Credit Agreement"), providing for extensions of credit to be made to Grantor (or one or more affiliates thereof) by Grantee and Lenders; and

WHEREAS, pursuant to the terms of a certain Guarantee and Collateral Agreement dated as of July 17, 2018, among Grantor, one or more of its affiliates and Grantee (as the same may be amended or otherwise modified from time to time, the "Collateral Agreement"), Grantor has granted to Grantee, for the benefit of Secured Parties, a security interest in substantially all of the assets of Grantor including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired Patents (as defined in the Collateral Agreement), and all products and proceeds thereof, to secure payment and performance of the Obligations;

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Credit Agreement and Collateral Agreement. The Credit Agreement and Collateral Agreement and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto. All terms capitalized but not otherwise defined herein shall have the same meanings herein as in the Collateral Agreement.


2. Grant and Reaffirmation of Grant of Security Interests. To secure payment and performance of the Obligations, Grantor hereby grants to Grantee, for the benefit of Secured Parties, and hereby reaffirms its prior grant pursuant to the Collateral Agreement of, a continuing security interest in Grantor's entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the "Patent Collateral"), whether now owned or existing and hereafter created, acquired or arising:

(i) each Patent and application for Patent listed on Schedule 1 annexed hereto, together with any reissues, continuations or extensions thereof; and

(ii) all products and proceeds of the foregoing, including, without limitation, any claim by Grantor against third parties for past, present or future infringement of any Patent.


IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

**WILDIFE LABORATORIES, LLC**

By:   
Name: Marcy Bliss  
Title: Chief Executive Officer, President, Treasurer and Secretary

Agreed and Accepted  
As of the Date First Written Above

MARANON CAPITAL, L.P.,  
as Agent



By Robert E. Kircher III  
Its Managing Director

**SCHEDULE 1**

**PATENTS**

<b>Description</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Owner<sup>1</sup></b>
“Pharmaceutical Combination For And Method Of Anesthetizing And Immobilizing Non-Domesticated Mammals”	7795263	September 14, 2010	Wildlife Laboratories, LLC
“Sedating And Immobilizing Non-Domesticated Mammals”	9339498	May 17, 2016	Wildlife Laboratories, LLC.

<sup>1</sup>Note – the registered owner of all registered intellectual property on this Schedule will be changed to Wildlife Laboratories, LLC with the USPTO following the Closing Date.